AI Summary
We reviewed 4 live results for idacio and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Biologics and Rheumatology.
Comparison Table
Recommended
Idacio
Source: Fresenius Kabi (Singapore) Pte Ltd
Description
Idacio is an adalimumab biosimilar registered in Singapore since 2021. It is available as a solution for injection in various formats including pre-filled pens, syringes, and vials (40mg/0.8ml). It is used for the treatment of immune-mediated inflammatory diseases.
Best for
vial-based administration, pen-based injection and HSA-registered treatments
View Details
Rating
Idacio (Adalimumab)
Source: Fresenius Kabi Philippines, Inc.
Description
Idacio is a citrate-free adalimumab biosimilar biologic medicine manufactured by Fresenius Kabi. Delivered as a 40 mg/0.8 mL solution for subcutaneous injection, it is available in prefilled pen (auto-injector) and prefilled syringe formats. It is indicated for treating chronic inflammatory conditions such as Rheumatoid Arthritis, Psoriatic Arthritis, Crohn’s Disease, and Ulcerative Colitis, providing a highly similar alternative to the reference product Humira.
Best for
rheumatoid arthritis treatment, inflammatory bowel disease therapy, citrate-free injection preference and adalimumab biosimilar therapy
View Details
Rating
Idacio (adalimumab)
Source: Fresenius Kabi
Description
Idacio is a biosimilar biologic medication containing adalimumab, a TNF-alpha inhibitor used to treat a wide range of inflammatory conditions. These include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis. The medication is typically provided as a 40 mg/0.8 mL solution for subcutaneous injection, available in formats such as a single-dose pre-filled pen (autoinjector), a pre-filled syringe, or a single-dose vial for pediatric or specific dosing needs. As a biosimilar, it offers a clinically equivalent and often more accessible alternative to the reference product Humira.
Best for
rheumatoid arthritis treatment, psoriasis management, Crohn’s disease patients, biosimilar medication seekers and subcutaneous injection therapy
View Details
Rating
| Compare | Idacio | Idacio (Adalimumab) | Idacio (adalimumab) |
|---|---|---|---|
| Source | Fresenius Kabi (Singapore) Pte Ltd | Fresenius Kabi Philippines, Inc. | Fresenius Kabi |
| Description | Idacio is an adalimumab biosimilar registered in Singapore since 2021. It is available as a solution for injection in various formats including pre-filled pens, syringes, and vials (40mg/0.8ml). It is used for the treatment of immune-mediated inflammatory diseases. | Idacio is a citrate-free adalimumab biosimilar biologic medicine manufactured by Fresenius Kabi. Delivered as a 40 mg/0.8 mL solution for subcutaneous injection, it is available in prefilled pen (auto-injector) and prefilled syringe formats. It is indicated for treating chronic inflammatory conditions such as Rheumatoid Arthritis, Psoriatic Arthritis, Crohn’s Disease, and Ulcerative Colitis, providing a highly similar alternative to the reference product Humira. | Idacio is a biosimilar biologic medication containing adalimumab, a TNF-alpha inhibitor used to treat a wide range of inflammatory conditions. These include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis. The medication is typically provided as a 40 mg/0.8 mL solution for subcutaneous injection, available in formats such as a single-dose pre-filled pen (autoinjector), a pre-filled syringe, or a single-dose vial for pediatric or specific dosing needs. As a biosimilar, it offers a clinically equivalent and often more accessible alternative to the reference product Humira. |
| Best for | vial-based administration, pen-based injection and HSA-registered treatments | rheumatoid arthritis treatment, inflammatory bowel disease therapy, citrate-free injection preference and adalimumab biosimilar therapy | rheumatoid arthritis treatment, psoriasis management, Crohn’s disease patients, biosimilar medication seekers and subcutaneous injection therapy |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"Idacio from Fresenius Kabi (Singapore) Pte Ltd."
I picked this because One of the few biosimilar options that includes a vial format for specific clinical needs.
Share this search
Related Finds